Vaxart, Inc. Files 8-K for Material Definitive Agreement

TL;DR

Vaxart signed a big deal, details TBD.

AI Summary

On December 20, 2024, Vaxart, Inc. entered into a material definitive agreement. The filing does not disclose the specific nature of the agreement or any associated dollar amounts or parties involved.

Why It Matters

This filing indicates a significant new contract or partnership for Vaxart, Inc., which could impact its future business operations and financial performance.

Risk Assessment

Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and implications of the material definitive agreement.

Key Players & Entities

• Vaxart, Inc. (company) — Registrant
• December 20, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value VXRT The Nasdaq Capital M
• $460.7 m — funding to the Company to approximately $460.7 million, representing an increase of appr
• $4.6 m — presenting an increase of approximately $4.6 million, and (ii) increased the total amo
• $134.2 m — available for payment to approximately $134.2 million, representing an increase of appr
• $37.7 million — presenting an increase of approximately $37.7 million. A portion of the additional funding is

Filing Documents

• vxrt20241227_8k.htm (8-K) — 26KB
• 0001437749-24-038436.txt ( ) — 155KB
• vxrt-20241220.xsd (EX-101.SCH) — 3KB
• vxrt-20241220_def.xml (EX-101.DEF) — 11KB
• vxrt-20241220_lab.xml (EX-101.LAB) — 15KB
• vxrt-20241220_pre.xml (EX-101.PRE) — 11KB
• vxrt20241227_8k_htm.xml (XML) — 3KB

01

Item 1.01. Entry into a Material Definitive Agreement. As previously disclosed on June 13, 2024, Vaxart, Inc. (the "Company") entered into an agreement (the "Project Agreement") with Advanced Technology International, the Consortium Management Firm of the Rapid Response Partnership Vehicle funded by the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services. Pursuant to the Project Agreement, the Company receives funding for a Phase 2b comparative study (the "Trial") evaluating the Company's oral pill XBB COVID-19 vaccine candidate against an mRNA vaccine comparator approved by the U.S. Food and Drug Administration. On December 20, 2024, the Company entered into Modification No. 4 (the "Modification") to the Project Agreement. The Modification (i) increased the total estimated ceiling for the funding to the Company to approximately $460.7 million, representing an increase of approximately $4.6 million, and (ii) increased the total amount of funding currently allotted to the Trial and available for payment to approximately $134.2 million, representing an increase of approximately $37.7 million. A portion of the additional funding is for the Company to acquire and distribute to clinical sites the mRNA comparator and other clinical materials for use in the Trial as well as to support clinical trial site readiness for the main efficacy and safety portion of the Trial. The foregoing description of the Modification does not purport to be complete and is qualified in its entirety by reference to the full text of the Modification, which will be filed as an exhibit to the Company's next periodic report.

Forward-Looking Statements

Forward-Looking Statements

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VAXART, INC. Dated: December 27, 2024 By: /s/ Steven Lo Steven Lo President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR